



BSW Formulary Update – February 2023

New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATED - [BSW Prescribing Guidelines for DRY EYE](#)** These guidelines have been developed with input from our three local acute Trust specialist teams (GWH, RUH, SFT) and represent locally approved cost-effective products. Please follow these guidelines for new patients. Advice on actively switching existing patients to cost-effective formulary options will follow.
- **UPDATED - [Summary of Intermittent and Real Time Continuous Glucose Monitoring \(CGM\) Systems available on FP10 for adults](#)**. Comparison table updated to reflect changes to Dexcom One transmitter procurement. Note that Freestyle Libre2 (isCGM) or DexcomOne (rtCGM) are BSW local preference choice of prescribable CGM.
- **UPDATED - [Prescribing guidance for Oral Semaglutide \(Rybelsus®▼\)](#)**. Updated to reflect recent change to GREEN TLS to allow the initiation of oral semaglutide by GP's or appropriate prescribers in Primary Care as an option during ongoing shortages with injectable GLP1 agonists.
- **NEW - [BaNES Combined Woundcare formularies](#)** – Local formularies for all Practice and District Nurses, Tissue Viability Nurses and Nursing homes based in the **BaNES** locality. All prescribing/ordering should be via Formeo, a non-prescription, online ordering platform for healthcare staff, in the first instance. For more info on Formeo see our Quick Ref Guides [here](#). Please note, our ICB works within the BSW & BNSSG Wound Care Formulary Group. Further information on this group can be found at [Formulary \(bswformulary.nhs.uk\)](#). Updated guidance for Swindon and Wiltshire localities will follow.

New additions to BSWformulary

- [Meropenem and vaborbactam](#) powder for concentrate for solution for infusion 1g/1g; [Delafloxacin](#) 300mg powder for concentrate for solution for infusion and 450mg tablets and [Cefazolin](#) 1g and 2g powder for solution for injection vials. All added with **RED** TLS for use on the recommendation of microbiology.
- [5% Lidocaine gel 15g tube \(Xylonor®\)](#). Added with **AMBER** TLS for topical anaesthesia in the buccal cavity in oral surgery patients.
- [Avatrombopag](#) 20mg tablet. Added with **RED** TLS for treating primary chronic immune thrombocytopenia in line with [NICE TA853](#).
- [Somatrogon](#) solution for injection. Added with **RED** TLS for treating growth disturbance in people 3 years and over in line with [NICE TA863](#).

Other BSWformulary updates

- BSW formulary team are working alongside specialist ophthalmology colleagues at GWH, RUH and SFT to align formulary options and TLS of drugs and medical devices used in the eye. Please



see the full chapter here [Formulary \(bswformulary.nhs.uk\)](https://www.bswformulary.nhs.uk). We are updating the prescribing messages on GP prescribing systems. In primary care, patients receiving prescriptions for eyedrops that are now assigned RED TLS, should be reviewed to consider if there is a clear indication and clear instructions on use and if the patient has input/review from secondary care. Queries on consideration for repatriating patients requiring ongoing use of eyedrops with RED TLS back to specialist can be raised via emailing bswicb.formulary@nhs.net in the first instance.

- 'Quick-link' tabs have been added to BSW formulary home page signposting to the
 - BSW Meds Op Medication Safety webpage [Medication Safety - Medicines \(bswtogether.org.uk\)](https://www.bswtogether.org.uk)
 - BSW ICB Community Pharmacy webpage [Pharmacies - BaNES, Swindon and Wiltshire ICB](#)
- Entries have been created in the palliative care chapter for [tranexamic acid 500mg tablets and 500mg/5mL ampoules](#) and for [adrenaline 1 in 1000 ampoules](#) for topical use (off-licence) in the management of bleeding malignant fungating wounds (MFW) in palliative care patients in the community. Approved for prescribing in primary care for this indication ONLY under the direction of palliative care specialists and in line with local guideline for management of MFW in the community available [here](#) (Link to guidance also included in relevant pall care chapter entries).
- [Novopen 6 and Novopen EchoPlus](#) replace Novopen 5 and Novopen Echo respectively.
- [Pholcodine linctus](#) moved from 'OTC' to **non-formulary** in line with EMA recommendation that patients should be advised to stop treatment with pholcodine medicines [EMA recommends withdrawal of pholcodine medicines from EU market | European Medicines Agency \(europa.eu\)](#)

What the BSW CCG formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.
- Working with our medicines safety leads and specialist anticoagulant pharmacist colleagues to review local guidance for DOACs in VTE and local guidance for use of LMWHs.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net